Updated:
Shandong Jincheng Pharmaceutical Group
Founded in 2004 by Zhao Yeqing and Zhao Shulun, Shandong Jincheng Pharmaceutical Group is a China-based corporate investor and operating company listed on the...
Shandong Jincheng Pharmaceutical Group
Founded in 2004 by Zhao Yeqing and Zhao Shulun, Shandong Jincheng Pharmaceutical Group is a China-based corporate investor and operating company listed on the Shenzhen Stock Exchange. The firm emerged from Zibo, Shandong province — a longstanding chemical and pharmaceutical manufacturing hub — and built an integrated platform spanning pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished drug products. The group generates its investment capital from operating cash flows rather than a discrete family office or external fund structure. The firm operates across the pharmaceutical value chain, with a particular concentration in cephalosporin side-chain intermediates, where it has established a dedicated production base in Zibo. Asset classes are dominated by direct industrial ownership: manufacturing facilities in Beijing, Shanghai, and Shandong anchor the physical footprint. The group also deploys capital into R&D partnerships with academic institutions, signing a comprehensive strategic cooperation agreement with Jinan University in 2024 and maintaining a separate collaboration with the Chinese Academy of Sciences focused on innovative therapeutics. These deals function as equity-linked or milestone-based investments rather than pure grant funding. The group maintains three manufacturing sites — its Zibo headquarters complex, a Beijing facility, and a Shanghai operation — alongside the cephalosporin intermediates base. December 2025 brought a governance shock: founder and actual controller Zhao Yeqing resigned from his chairman role following a China Securities Regulatory Commission investigation into alleged market manipulation. The firm also conducts philanthropy through Jincheng Pharmaceutical Charity Initiatives, though the scale and structure of this giving remain undisclosed. What distinguishes Jincheng from generic Chinese pharma listed companies is its dual identity as both a vertically integrated manufacturer and an R&D investor through formal institutional partnerships. Rather than a pure family office or venture arm, the firm's corporate balance sheet absorbs investment risk, and its academic collaborations function as a pipeline-sourcing engine. The 2025 leadership transition introduces unresolved succession and regulatory risk that will define the next phase of the group's investment posture.
General information
Firm type
Corporate Investor
Year founded
2004
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Zibo
Corporate office
No. 1 Shuangshan Road, Zichuan Economic Development Zone, Zibo, Shandong, China
Additional offices
Beijing, China · Shanghai, China
Principals
Zhao Yeqing
Founder, former Chairman and Actual Controller
Zhao Shulun
Founder
Sector focus
Frequently asked questions
Who controls investment decisions at Shandong Jincheng Pharmaceutical?
Investment decisions historically flowed through founder Zhao Yeqing, who served as chairman and actual controller until his December 2025 resignation following a CSRC investigation. The post-resignation governance structure has not been publicly detailed. The firm's corporate balance sheet, rather than a separate family office or investment committee, is the capital source for its pharmaceutical investments and R&D partnerships.
How does the firm fund its investments and R&D partnerships?
Jincheng uses operating cash flows from its pharmaceutical manufacturing business — intermediates, APIs, and finished products — to fund investments. It does not operate a disclosed external fund structure or raise third-party capital. R&D partnerships with Jinan University and the Chinese Academy of Sciences are structured as direct corporate collaborations rather than through a venture arm.
What is the firm's relationship to the Shenzhen Stock Exchange listing?
Shandong Jincheng Pharmaceutical Group is itself the listed entity. The public listing serves as both the corporate structure and the primary capital vehicle. There is no separate holding company, family office, or investment manager layered above the operating business — a structure common among Chinese industrial companies that use the public market as their main financing channel.
What pharmaceutical verticals does the firm actually own and operate?
The group owns manufacturing sites for pharmaceutical intermediates, active pharmaceutical ingredients, and finished drug products. A dedicated cephalosporin side-chain intermediates production base sits in Zibo. Physical assets include the Zibo headquarters complex, a Beijing manufacturing site, and a Shanghai facility. These are direct industrial holdings, not portfolio-company positions.
What happened with the CSRC investigation and founder resignation?
In December 2025, founder Zhao Yeqing stepped down as chairman and actual controller of the group after the China Securities Regulatory Commission opened an investigation into alleged market manipulation. The firm disclosed the resignation and investigation via Shenzhen Stock Exchange filings. The identity of Zhao's successor and any regulatory penalties have not been publicly finalized as of the latest available disclosures.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: